- Home
- BILL vs TERN Comparison
BILL vs TERN Comparison
Compare BILL & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILL | TERN |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BILL | TERN |
|---|---|---|
| Price | $49.14 | $37.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 10 |
| Target Price | ★ $60.64 | $48.60 |
| AVG Volume (30 Days) | ★ 4.1M | 2.3M |
| Earning Date | 02-05-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,551,979,000.00 | N/A |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $13.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.84 | N/A |
| 52 Week Low | $35.46 | $1.87 |
| 52 Week High | $98.00 | $48.26 |
Technical Indicators
Market Signals| Indicator | BILL | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 52.55 |
| Support Level | $35.46 | $34.99 |
| Resistance Level | $49.60 | $38.97 |
| Average True Range (ATR) | 2.48 | 1.97 |
| MACD | -0.72 | 0.04 |
| Stochastic Oscillator | 48.21 | 61.76 |
Price Performance
Historical ComparisonAbout BILL BILL Holdings Inc.
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.